ArticleJournal of orthopaedic surgery and research2025
Dickkopf-3 enhances the chondroprotective effect of chondrogenic progenitor cells in a rat model of posttraumatic osteoarthritis.
Article in Journal of orthopaedic surgery and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundOur previous work suggested biological potential alterations in chondrogenic progenitor cells (CPCs) during knee osteoarthritic progression. The Wnt pathway plays a pivotal role in osteoarthritis progression, and Dickkopf-3 (DKK3) is a noncanonical Wnt antagonist. However, it remains unclear whether the DKK3 expression level is involved in the changes of the biological characteristics of CPCs during OA progression. This study aimed to explore the difference of DKK3 expression in osteochondral specimens and corresponding CPCs during osteoarthritis progression. Furthermore, the influence of DKK3 on the in vitro characteristics and in vivo therapeutic efficacy of CPCs was investigated.
methodsThe expression levels of DKK3 in human paired grade 1-2 and grade 3-4 osteoarthritic cartilage and corresponding CPCs were determined via immunohistochemical staining and western blotting, respectively. CPCs were isolated, cultured and characterized for their self-renewal and multidifferentiation abilities. Then, the CPCs were transfected with Lentiviral-DKK3 or siRNA to overexpress or knock down DKK3, respectively. The chondrogenic potential of the CPCs was examined via pellet staining and gene detection. The expression levels of inflammatory factors in different groups of CPCs were examined via qRT‒PCR and ELISA. The activation status of β-catenin in Wnt signalling was investigated via confocal microscopy. The in vivo chondroprotective effects of LV-DKK3 and Si-DKK3-transgenic CPCs were examined in a rat model of posttraumatic osteoarthritis.
resultsThe DKK3 expression level was significantly increased in Grade 3-4 cartilage compared with Grade 1-2 cartilage. However, the DKK3 expression level was significantly lower in Grade 3-4 CPCs than in Grade 1-2 CPCs. The overexpression of DKK3 significantly increased CPC chondrogenic potential and inhibited the expression of catabolic factors, whereas the knockdown of DKK3 had the opposite effects, decreasing CPC chondrogenic potential and increasing the expression of catabolic factors. Wnt signalling was significantly inhibited by DKK3. The in vivo results suggested that lentivirus-induced LV-dkk3 significantly delayed the progression of experimental OA, whereas lentivirus-mediated Si-DKK3, which aimed to silence endogenous DKK3, accelerated the progression of experimental OA.
conclusionOur results suggest that DKK3 has a chondroprotective effect during osteoarthritis progression and that CPCs may be functional targets. The underlying mechanisms of DKK3 may include enhancing CPC chondrogenic capacity and inhibiting Wnt-mediated expression of catabolic factors and matrix remodelling activities. These findings indicate that DKK3 is a potential therapeutic target for CPC-mediated OA treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.